Clinical application of stem cell therapy in Parkinson's disease.
Clinical application of stem cell therapy in Parkinson's disease.
复制标题
DOI：
10.1186/1741-7015-10-1
复制
发表时间：
2012-01-04
期刊：
影响因子：
9.3
通讯作者：
Lindvall O
中科院分区：
文献类型：
--
作者：
Politis M;Lindvall O
Cell replacement therapies in Parkinson's disease (PD) aim to provide long-lasting relief of patients' symptoms. Previous clinical trials using transplantation of human fetal ventral mesencephalic (hfVM) tissue in the striata of PD patients have provided proof-of-principle that such grafts can restore striatal dopaminergic (DA-ergic) function. The transplants survive, reinnervate the striatum, and generate adequate symptomatic relief in some patients for more than a decade following operation. However, the initial clinical trials lacked homogeneity of outcomes and were hindered by the development of troublesome graft-induced dyskinesias in a subgroup of patients. Although recent knowledge has provided insights for overcoming these obstacles, it is unlikely that transplantation of hfVM tissue will become routine treatment for PD owing to problems with tissue availability and standardization of the grafts. The main focus now is on producing DA-ergic neuroblasts for transplantation from stem cells (SCs). There is a range of emerging sources of SCs for generating a DA-ergic fate in vitro. However, the translation of these efforts in vivo currently lacks efficacy and sustainability. A successful, clinically competitive SC therapy in PD needs to produce long-lasting symptomatic relief without side effects while counteracting PD progression.
登录
查看更多内容
克隆衍生的人类胚胎干细胞系在长期培养过程中保持多能性和增殖潜力
影响因子：
2.7
作者：
Amit, M;Carpenter, MK;Thomson, JA
通讯作者：
Thomson, JA
影响因子：
14.5
作者：
Mendez, I;Sanchez-Pernaute, R;Isacson, O
通讯作者：
Isacson, O
影响因子：
11.2
作者：
Olanow, CW;Goetz, CG;Freeman, TB
通讯作者：
Freeman, TB
影响因子：
5.2
作者：
Brederlau, Anke;Correia, Ana Sofia;Li, Jia-Yi
通讯作者：
Li, Jia-Yi
影响因子：
4
作者：
Cai, Jingli;Yang, Ming;Iacovitti, Lorraine
通讯作者：
Iacovitti, Lorraine